Solitaire-Iv: Results Of A Phase 3 Iv To Oral Trial In Adults With Community-Acquired Bacterial Pneumonia Comparing Solithromycin To Moxifloxacin

被引：0
|
作者：
File, T. M., Jr. [1 ]
Rewerska, B. [2 ]
Tanaseanu, C. M. [3 ]
Mihailovic-Vucinic, V. [4 ]
Gonong, J. R. [5 ]
Jamieson, B. D. [6 ]
Taylor, D. [6 ]
Sheets, A. [6 ]
Keedy, K. [6 ]
Oldach, D. W. [6 ]
Fernandes, P. [6 ]
机构：
[1] Summa Hlth Syst, Akron, OH USA
[2] Diamond Clin, Krakow, Poland
[3] St Pantelimon Emergency Clin Hosp, Bucharest, Romania
[4] Clin Ctr Serbia, Belgrade, Serbia
[5] Lung Ctr Philippines, Manila, Philippines
[6] Cempra Inc, Chapel Hill, NC USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2116
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities
    Thomas M. File
    Elizabeth Alexander
    Lisa Goldberg
    Anita F. Das
    Christian Sandrock
    Susanne Paukner
    Gregory J. Moran
    BMC Pulmonary Medicine, 21
  • [42] A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia
    Li, Ying
    Zhu, Demei
    Peng, Yiqiang
    Tong, Zhaohui
    Ma, Zhuang
    Xu, Jinfu
    Sung, Shenghua
    Tang, Huaping
    Xiu, Qingyu
    Liang, Yongjie
    Wang, Xiongbiao
    Lv, Xiaoju
    Dai, Yuanrong
    Zhu, Yingqun
    Qu, Yuejin
    Xu, Kaifeng
    Huang, Yijiang
    Wu, Shiman
    Lai, Guoxiang
    Li, Xi
    Han, Xiaowen
    Yang, Zegang
    Sheng, Jifang
    Liu, Zhuola
    Li, Hui
    Chen, Yiqiang
    Zhu, Huili
    Zhang, Yingyuan
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (04) : 693 - 701
  • [43] Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin
    Paukner, Susanne
    Goldberg, Lisa
    Alexander, Elizabeth
    Das, Anita F.
    Heinrich, Stefanie
    Patel, Pritty
    Moran, Gregory J.
    Sandrock, Christian
    File Jr, Thomas M.
    Vidal, Jorge E.
    Waites, Ken B.
    Gelone, Steven P.
    Schranz, Jennifer
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2022, 29 : 434 - 443
  • [44] Microbiological Outcomes of 2 Multicenter Phase 3 Clinical Trials of Ceftaroline in Community-acquired Bacterial Pneumonia
    Critchley, I.
    Friedland, D.
    Eckburg, P.
    Jandourek, A.
    Han, S. -H.
    Thye, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [45] DELAFLOXACIN IN THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA: OUTCOMES FROM A GLOBAL PHASE-3 STUDY
    Cammarata, Sue
    Horcajada, Juan P.
    Alvarez-Sala, Rodolfo
    Nitu, Floarea-Mimi
    Quintas, Megan
    Lawrence, Laura
    Li, Yang
    CHEST, 2019, 156 (04) : 412A - 413A
  • [46] Early Clinical Response of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by PORT Risk Class: Results from the OPTIC Study
    Ramirez, J. A.
    Garrity-Ryan, L.
    Eckburg, P. B.
    Das, A.
    Kirsch, C.
    Manley, A.
    Tzanis, E.
    McGovern, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [47] Late Breaking Abstract - Adjunctive treatment with oral dexamethasone in adults hospitalised with community-acquired pneumonia: a randomised clinical trial
    Wittermans, Esther
    Vestjens, Stefan
    Spoorenberg, Simone
    Blok, Willem
    Grutters, Jan
    Janssen, Ro B.
    Rijkers, Ger
    Smeenk, Frank
    Voorn, Paul
    Van De Garde, Ewoudt
    Bos, Willem Jan
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [48] Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials
    Paukner, Susanne
    Mariano, David
    Das, Anita F.
    Moran, Gregory J.
    Sandrock, Christian
    Waites, Ken B.
    File, Thomas M., Jr.
    ANTIBIOTICS-BASEL, 2021, 10 (12):
  • [49] Economic evaluation demonstrates that moxifloxacin IV/PO monotherapy is cost-effective to the Spanish National Healthcare System when compared to IV/PO amoxicillin/clavulanate ± clarithromycin in the treatment of community-acquired pneumonia
    Drummond, M
    Becker, D
    Hux, M
    Chancellor, J
    Duprat-Lomon, I
    Sagnier, PP
    VALUE IN HEALTH, 2002, 5 (06) : 565 - 565
  • [50] Cost-effectiveness of IV-to-oral switch therapy - Azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia
    Paladino, JA
    Gudgel, LD
    Forrest, A
    Niederman, MS
    CHEST, 2002, 122 (04) : 1271 - 1279
12345